Key result
Recombinant 3K3A-APC, an engineered variant of activated protein C lacking most anticoagulant activity, provides neuroprotection in preclinical models and is in ongoing trials for ischemic stroke.
Population
Preclinical injury models, including murine ischemic stroke models
Design
Review
Authors
Loading...
May inform targeted APC therapies for ischemic stroke; extends preclinical receptor data but leaves clinical translation open.
Recombinant APC and its variant 3K3A-APC demonstrate neuroprotective and anti-inflammatory properties in preclinical ischemic stroke models, supporting ongoing clinical trials.
Griffin et al. (2016) conducted a review in Ischemic stroke. Recombinant 3K3A-APC was evaluated. Recombinant 3K3A-APC, an engineered variant of activated protein C lacking most anticoagulant activity, provides neuroprotection in preclinical models and is in ongoing trials for ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: